B of A Securities Downgrades Amphastar Pharma to Underperform, Lowers Price Target to $20
Bank of America Securities downgrades Amphastar Pharma to Underperform.
B of A Securities analyst Jason Gerberry downgrades Amphastar Pharma (NASDAQ: AMPH ) from Neutral to Underperform and lowers the price target from $25 to $20.